Karyopharm Therapeutics (KPTI) Invested Capital (2012 - 2025)

Karyopharm Therapeutics has reported Invested Capital for 14 years, with the latest figure at -$271.9 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital fell 46.18% year-over-year to -$271.9 million; the trailing twelve-month figure through Dec 2025 stood at -$271.9 million (down 46.18% YoY), and the FY2025 full-year result was -$271.9 million, down 46.18% from the prior year.
• Invested Capital for Q4 2025 stood at -$271.9 million, down from -$256.8 million in the prior quarter.
• The five-year high for Invested Capital was -$16.7 million in Q4 2022, with the low at -$271.9 million in Q4 2025.
• Historically, Invested Capital has averaged -$132.6 million across 5 years, with a median of -$129.1 million in 2021.
• Annual changes were most pronounced in 2022 — Invested Capital surged 79.09% — and 2023, when it plunged 717.76%.
• Karyopharm Therapeutics' Invested Capital stood at -$79.7 million in 2021, then surged by 79.09% to -$16.7 million in 2022, then sank by 717.76% to -$136.2 million in 2023, then tumbled by 36.57% to -$186.0 million in 2024, then slumped by 46.18% to -$271.9 million in 2025.
• The last three Invested Capital figures came in at -$271.9 million (Q4 2025), -$256.8 million (Q3 2025), and -$232.7 million (Q2 2025), per Business Quant data.